News

STAMFORD ADVOCATE | 12.6.18

Stamford-Based Sema4 to Co-Lead Asthma Study

“Health care testing company Sema4 announced this week it would help launch an asthma study that aims to advance diagnoses and treatments of the chronic respiratory disease. Sema4, the Mount Sinai Health System and Sanofi are partnering on the five-year assessment of nearly 1,200 asthma patients in the U.S. to better understand the source of asthma attacks, the disease’s varying impact on patients, and the potential of certain therapies. For Sema4, the findings would help to develop asthma tests…”
READ MORE
FIERCE BIOTECH | 12.5.18

Sanofi, Sema4 Launch 5-Year, Real-World Digital Asthma Study

“Sanofi and Sema4 have launched a five-year longitudinal study of nearly 1,200 asthma patients, with plans to incorporate digital tools to develop a better understanding of the disease. Alongside collections of clinical, genomic and environmental data, it will employ connected inhalers to track how the disease affects some individuals differently than others, in what Sanofi describes as one of the largest studies of its kind…”
READ MORE
SEMA4 PRESS RELEASE | 12.04.18

Sanofi, Sema4, Mount Sinai Collaborate on Largest Asthma Study of Its Kind

“Sema4 and the Mount Sinai Health System today announced the launch of a five-year collaborative study with Sanofi designed to provide new insights into the biological mechanisms and other factors implicated in asthma. The project will follow nearly 1,200 people with asthma and collect a range of data — from traditional clinical data to genomics, immunological, environmental, and sensor data from mobile devices — to enable sophisticated analysis and advanced network modeling of this complex disease…”
READ MORE
CLINICALOMICS | 12.04.18

Sema4, Mt. Sinai Collaborate with Sanofi on Asthma Study

“Asthma is an incredibly complex condition associated with genetics, environmental factors, activity levels, the immune system, and more,” said Sema4 CEO, Eric Schadt… “We believe the only way to fully understand asthma is by using sophisticated modeling tools to mine the rich, multi-dimensional data set we aim to generate in this study.”
READ MORE
SEMA4 NEWS | 11.30.18

Sema4 Natalis at The Westchester – Activate Your Holiday Promo Code Today

This holiday season, our Sema4 Natalis team is on hand at The Westchester to help families understand the importance of deeper insight into childhood health. We are passionate about providing parents access to the latest in genetic testing technology to further prepare them for the future, which is why we have created a special holiday promotion.
READ MORE
SEMA4 PRESS RELEASE | 10.25.18

New Hope for Drug Discovery in Schizophrenia, Other Diseases with Improved Screening Models

“Scientists from the Icahn School of Medicine at Mount Sinai, Eli Lilly and Company, and Sema4 released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods. These findings could pave the way for streamlined drug discovery, particularly for diseases such as schizophrenia that have seen little therapeutic innovation…”
READ MORE
TECH NATION | 10.02.18

All That Personal Medical Data

“Take Alzheimer’s or heart disease, there may be a hundred different causes or pathways at play that may be affected in you… but completely different ones that affect another person with the same disease. It is about ultimately personalizing medicine in a precise way that is highly accurate, taking all the information into account, giving the most actionable guidance on what you should do to correct the problem…”
READ MORE
CBS | 10.01.18

Testing Babies: Do Parents Have Too Much Information About Their Kids?

“Every parent worries when it comes to the health of their child. Now, a simple test can give mothers and fathers a glimpse into their infant’s medical future…”
READ MORE
SEMA4 PRESS RELEASE | 08.21.18

Sema4 Applies Data-Driven Approach to Develop and Launch New NIPT and Expanded Carrier Screen Tests

“Sema4 today announced the launch of two reproductive health tests: the new Sema4 Noninvasive Prenatal Select and an enhanced version of its Expanded Carrier Screen. These products, developed with an informatics-driven approach using Sema4’s Health Intelligence Platform (SHIP), add to the company’s industry-leading portfolio of tests designed to support providers and patients from preconception to pediatrics…”
READ MORE
BLOOMBERG | 06.19.18

Data is Key to Medical Care

“At Sema4, we focus on delivering state of the art testing on patients in their normal health course. So, think of genomic testing, carrier screening, non-invasive prenatal testing, somatic tumor profiling. And, as we’re providing that state of the art testing, we are also aggregating lots of information around them regarding their condition, their electronic medical record, and even collecting information off devices, basically to better interpret the state of that individual, what kind of care they should receive, and what kind of disease or conditions they are at risk for…”
READ MORE